YMT compared with GYRE: revenue, margins and what each company keeps, and the suppliers and customers both name

YMTYimutian Inc.

Mkt capRevenueRevenue

GYREGyre Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

YMTYimutian Inc.

GYREGyre Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

YMTYimutian Inc.

0.29▼−2.60%· post 0.29

Mkt cap$25.2MRevenue—Revenue—

GYREGyre Therapeutics, Inc.

4.43▼−0.23%· post 4.44

ClosedNov 4 '26

Mkt cap$495.1MRevenue$29MQ2 FY26Revenue$120MFY25

Compare

ClosedNov 4 '26

YMTYimutian Inc.

GYREGyre Therapeutics, Inc.

0.29▼−2.60%post 0.29

Price

4.43▼−0.23%post 4.44

$25.2M

Mkt cap

$495.1M

—

Revenue

$29MQ2 FY26

—

Revenue

$120MFY25

YMT0.29▼−2.60%vsGYRE4.43▼−0.23%ClosedNov 4 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

YMT: latest quarter not drawable. GYRE: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only YMT 0

None

Shared 0

No disclosed counterparties: YMT.

Only GYRE 4

—Jiangsu Wangao Pharmaceuticalsunlistedsupplier

—Nanjing Healthnice Pharmaceutical Technologyunlistedsupplier

—WuXi STAunlistedsupplier

—GNIunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

YMT, solidGYRE, dashed